

**ABSTRACT****IMMUNOTHERAPEUTIC METHODS AND MOLECULES**

5 A peptide comprising an HLA-binding peptide of human CD45 polypeptide or a portion or variant of said peptide provided that the peptide is not the intact human CD45 polypeptide.

Preferably, the peptide comprises the amino acid sequence FLYDVIAST (SEQ ID NO:1) or ALIAFLAFL (SEQ ID NO:2) or KLFTAQLNV (SEQ ID NO:3) or MTWEQKATV (SEQ ID NO:4) or NLSELHPYL (SEQ ID NO:5) or VNLSELHPYL (SEQ ID NO:6) or LLAFGFAFL (SEQ ID NO:7) or YLYNKETKL (SEQ ID NO:8) or LILDVPPGV (SEQ ID NO:9) or TLILDVPPGV (SEQ ID NO:10) or ILYNNHKFT (SEQ ID NO:11) or ILPYDYNRV (SEQ ID NO:12) or YILIHQALV (SEQ ID NO:13) or FQLHDCTQV (SEQ ID NO:14) or KLLAFLGFAFL (SEQ ID NO:15) or YQYQYTNWSV (SEQ ID NO:16) or a portion or variant of any of these. Methods of leukaemia immunotherapy using specific cytotoxic T lymphocytes are also disclosed.